MedTrace Logo

Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma

NCT04598009 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2025-09-03

No results posted yet for this study

Summary

This phase II trial studies how well binimetinib and imatinib work in treating patients with stage III-IV KIT-mutant melanoma that cannot be removed by surgery (unresectable). Binimetinib and imatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving binimetinib and imatinib may help treat patients with KIT-mutant melanoma.

Conditions

  • Melanoma Stage III
  • Melanoma Stage IV

Interventions

DRUG

Binimetinib

Taken orally (PO) twice a day (BID)

DRUG

Imatinib

Taken orally (PO) once a day (QD)

Sponsors & Collaborators

Principal Investigators

  • Katy Tsai, MD · University of California, San Francisco

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-03
Primary Completion
2026-05-31
Completion
2027-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04598009 on ClinicalTrials.gov